CN109090597A - 一种辅助降三高组合物及其制备方法和应用 - Google Patents
一种辅助降三高组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN109090597A CN109090597A CN201810746064.4A CN201810746064A CN109090597A CN 109090597 A CN109090597 A CN 109090597A CN 201810746064 A CN201810746064 A CN 201810746064A CN 109090597 A CN109090597 A CN 109090597A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- hypertension
- composition
- hyperglycemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 40
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 34
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 121
- 235000013312 flour Nutrition 0.000 claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 21
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 16
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 16
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 16
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 16
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 16
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 16
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 16
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 16
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 16
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 15
- 238000004040 coloring Methods 0.000 claims abstract description 15
- 235000013557 nattō Nutrition 0.000 claims abstract description 15
- 229920002752 Konjac Polymers 0.000 claims abstract description 14
- 241000169546 Lycium ruthenicum Species 0.000 claims abstract description 14
- 235000005979 Citrus limon Nutrition 0.000 claims abstract description 13
- 244000131522 Citrus pyriformis Species 0.000 claims abstract description 13
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims abstract description 13
- 240000003768 Solanum lycopersicum Species 0.000 claims abstract description 13
- 241000209140 Triticum Species 0.000 claims abstract description 13
- 235000021307 Triticum Nutrition 0.000 claims abstract description 13
- 229940105902 mint extract Drugs 0.000 claims abstract description 13
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 12
- 241000237636 Pheretima Species 0.000 claims abstract description 12
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 12
- 240000008042 Zea mays Species 0.000 claims abstract description 12
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 12
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 12
- 235000005822 corn Nutrition 0.000 claims abstract description 12
- 235000012907 honey Nutrition 0.000 claims abstract description 12
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 11
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 11
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 4
- 235000004879 dioscorea Nutrition 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 6
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 4
- 230000001315 anti-hyperlipaemic effect Effects 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940111793 eggplant extract Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 28
- 239000008280 blood Substances 0.000 abstract description 28
- 239000003814 drug Substances 0.000 abstract description 14
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 4
- 230000000050 nutritive effect Effects 0.000 abstract description 3
- 238000007086 side reaction Methods 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 41
- 230000000694 effects Effects 0.000 description 23
- 235000012000 cholesterol Nutrition 0.000 description 18
- 241001092040 Crataegus Species 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 235000013399 edible fruits Nutrition 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- -1 lipid alcohols Chemical class 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 229940026314 red yeast rice Drugs 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 235000002722 Dioscorea batatas Nutrition 0.000 description 3
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 3
- 240000001811 Dioscorea oppositifolia Species 0.000 description 3
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000361919 Metaphire sieboldi Species 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000010977 jade Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 206010007026 Calculus urethral Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 235000021258 carbohydrate absorption Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- XXKNHBAFFJINCK-RVEJDSBJSA-N monascin Chemical compound C([C@@H]1[C@H](C(O[C@@]1(C)C1=O)=O)C(=O)CCCCC)C2=C1COC(\C=C\C)=C2 XXKNHBAFFJINCK-RVEJDSBJSA-N 0.000 description 1
- GFSMXLMQRWMHON-UHFFFAOYSA-N monascin Natural products CCCCCC(=O)C1C2C=C3C=C(OC=C3C(=O)C2(C)OC1=O)C=CC GFSMXLMQRWMHON-UHFFFAOYSA-N 0.000 description 1
- GIKQHOXMDCDAPT-UHFFFAOYSA-N monascusone B Natural products CC=CC1=CC2=C(CO1)C(=O)C3(C)OC(=O)C(C3C2)C(=O)C GIKQHOXMDCDAPT-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940086319 nattokinase Drugs 0.000 description 1
- 108010073682 nattokinase Proteins 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 201000009160 urethral calculus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种辅助降三高组合物,所述组合物由以下重量份数的原料制备而成:地龙蛋白粉0.1‑0.2份、红曲粉0.03‑0.08份、纳豆粉0.03‑0.05份、黑番茄提取物0.02‑0.04份、山楂粉0.02‑0.04份、红枣粉0.02‑0.04份、薄荷提取物0.03‑0.09份、魔芋粉0.03‑0.08份、山药粉0.01‑0.03份、麦苗粉0.01‑0.04份、柠檬粉0.01‑0.04份、水蜜桃提取物0.01‑0.04份、玉米低聚肽粉0.05‑0.1份、黑枸杞粉0.03‑0.08份。本发明提供的辅助降三高组合物成本低,营养价值高,能够有效辅助三高下降,且能明显减少辅助降压、降糖、降血脂药物所产生的副反应。本发明还公开了上述辅助降三高组合物的制备方法和应用。
Description
技术领域
本发明涉及保健食品技术领域,具体涉及一种辅助降三高组合物及制备方法和应用。
背景技术
“三高症”是指高血压、高血糖(糖尿病)和高脂血症。是现代社会所派生出来的“富贵病”,可能单独存在,也可能相互关联。由于长时间饮食习惯问题,饮食中脂类过多,醇类过多。同时又没有合理的运动促进脂类醇类的代谢,导致体内脂类醇类物质逐渐增多,掺杂在血液中,使毛细血管堵塞,随着时间的推移,脂类醇类物质容易和体内游离的矿物质离子结合,形成血栓。血栓容易在血管的拐角处,或者瓶颈处堆积,钙化。同时血栓越来越多,使血管直径缩小。心脏为了保持足够的供血量,就增加血压,造成高血压疾病。血脂主要是指血清中的胆固醇和甘油三酯。无论是胆固醇含量增高,还是甘油三脂的含量增高,或是两者皆增高,统称为高脂血症。高血脂可以引起血管栓塞;高血压可以引起脑出血和脑血管破裂;高血糖可以引起糖尿病。目前三高人群数量在不断增加,而治疗方法主要是依靠中西医药物,辅助饮食控制和运动。
发明内容
本发明的目的在于提供一种辅助降三高组合物,用以解决现有的治疗方法主要是依靠中西医药物,辅助饮食控制和运动的问题。
为实现上述目的,本发明的技术方案为:
一种辅助降三高组合物,所述组合物由以下重量份数的原料制备而成:地龙蛋白粉0.1-0.2份、红曲粉0.03-0.08份、纳豆粉0.03-0.05份、黑番茄提取物0.02-0.04份、山楂粉0.02-0.04份、红枣粉0.02-0.04份、薄荷提取物0.03-0.09份、魔芋粉0.03-0.08份、山药粉0.01-0.03份、麦苗粉0.01-0.04份、柠檬粉0.01-0.04份、水蜜桃提取物0.01-0.04份、玉米低聚肽粉0.05-0.1份、黑枸杞粉0.03-0.08份。
上述各原料在市场上均可买到。
作为一种优选的方案,所述组合物由以下重量份数的原料制备而成:地龙蛋白粉0.13-0.17份、红曲粉0.04-0.07份、纳豆粉0.04-0.05份、黑番茄提取物0.03-0.04份、山楂粉0.03-0.04份、红枣粉0.03-0.04份、薄荷提取物0.05-0.07份、魔芋粉0.04-0.07份、山药粉0.02-0.03份、麦苗粉0.02-0.03份、柠檬粉0.02-0.03份、水蜜桃提取物0.02-0.03份、玉米低聚肽粉0.06-0.08份、黑枸杞粉0.04-0.07份。
作为一种优选的方案,所述组合物由以下重量份数的原料制备而成:地龙蛋白粉0.15份、红曲粉0.05份、纳豆粉0.045份、黑番茄提取物0.035份、山楂粉0.035份、红枣粉0.035份、薄荷提取物0.06份、魔芋粉0.05份、山药粉0.025份、麦苗粉0.025份、柠檬粉0.025份、水蜜桃提取物0.025份、玉米低聚肽粉0.07份、黑枸杞粉0.05份。
作为一种优选的方案,所述组合物为压片制剂。
本发明的第二个目的是提供一种如上所述的辅助降三高组合物的制备方法,所述方法如下:
称取相应重量份数的各原料,混合均匀,压制成片。
本发明的第三个目的是提供一种如上所述的组合物在降高血压、降高血糖、降高血脂药物中的应用。
本发明具有如下优点:
本发明所得的压片,成本低,营养价值高,能够有效辅助三高下降,且能明显减少辅助降压、降糖、降血脂药物所产生的副反应。
其中,地龙蛋白质中含有多种游离氨基酸,它们是地龙最主要的营养成分。服用活性地龙蛋白后,随着血栓的溶解,血管的软化、微循环的改善,降低了血液粘稠度,使异常的血液流变学指标恢复正常,使甲皱微循环检测由异常转为正常,从而消除了发生心脑血管意外的隐患。
活性地龙蛋白通过恢复血液弹性、溶解血栓、改善微循环而改善管围状态,降低血流外周阻力,降低血液粘稠度而具有稳定的降压作用。原发性高血压病服用后,可使血压控制在正常后接近正常的水平;重度高血压病或心脑血管并发高血压,服地龙蛋白后能增强其它降压药的降压作用,减少其剂量和毒副作用,同时地龙蛋白通过改善血液质量和外周阻力对低血压具有调节作用。由于活性地龙蛋白良性的正源综合效应改善了人体多种机能,改善了机体的内环境,促进了胰岛功能的恢复,服地龙蛋白后有一定的降糖作用。
红曲粉具有降低胆固醇和甘油三酯的作用:专家从红曲菌中分离出一种类似于他汀类药物的特殊成分“红曲素”,它可以抑制甲基戊二酰辅酶A的活性(后者正是合成胆固醇的关键酶),从而有降低胆固醇的作用。研究表明,红曲可以降低血液中甘油三酯和低密度脂蛋白胆固醇,增加高密度脂蛋白胆固醇,使血管不易堵塞。红曲粉具有降血压的作用:红曲次生代谢产物γ-氨基丁酸作为促进脑神经传导物质,根据许多实验证实,具有良好的降血压效果。红曲粉具有降血糖的作用:红曲中含有抑制碳水化合物吸收的物质,具有显著的降血糖效果。研究发现,吃低脂肪、低胆固醇的饮食,同时服用红曲提取物,能使人体总胆固醇大大降低。可见,红曲能抑制胆固醇的合成,降低人体对胆固醇的吸收,具有降低血脂的作用,可有效控制动脉粥样硬化等疾病。
纳豆粉,具有预防高血压的作用。纳豆中的纳豆菌、纳豆激酶、小肽、氨基酸等多种活性物质,能彻底清除垃圾,使人体血液循环和组织器官恢复正常功能,纳豆对脑血栓、心肌梗塞等心脑血管症状有着显著效果。
黑番茄提取物,药食兼用,是番茄家族中的珍品,具有浓郁的水果香味,营养价值高,味道非常甜,特别适合鲜食,含有比红番茄中高10倍的茄红素和维生素C及抗氧化剂,及易被人体吸收。
山楂粉具有强心、降血脂、降血压的作用:山楂粉能显著降低血清胆固醇及甘油三酯,有效防治动脉粥样硬化;山楂还能通过增强心肌收缩力、增加心输出量、扩张冠状动脉血管、增加冠脉血流量、降低心肌耗氧量等起到强心和预防心绞痛的作用。此外,山楂粉中的总黄酮有扩张血管和持久降压的作用。
红枣粉中的维生素P含量为所有果蔬之冠,其具有维持毛细血管通透性,改善微循环从而预防动脉硬化的作用,还可促进维生素C在人体内积蓄。另外,红枣中所含的皂类物质,具有调节人体代谢、增强免疫力、抗炎、抗变态反应、降低血糖和胆固醇含量等作用。
薄荷提取物,味辛,性凉;归肺、肝经;清香升散;具有疏风散热,清头目,利咽喉,透疹,解郁的功效;主治风热表症,头痛眩晕,目赤肿痛,咽痛声哑,鼻渊,牙痛,麻疹不透,隐疹瘙痒,肝郁胁痛脘胀,瘰疬结核。
魔芋粉,性寒、辛,有毒;可活血化瘀,解毒消肿,宽肠通便,化痰软坚;主治降血压、降血糖、瘰疬痰核、损伤瘀肿、便秘腹痛、咽喉肿痛、牙龈肿痛等症。另外,魔芋还具有补钙、平衡盐分、洁胃、整肠、排毒等作用。
山药粉,中医认为山药具有健脾、补肺、固肾、益精等多种功效。并且对肺虚咳嗽、脾虚泄泻、肾虚遗精、带下及小便频繁等症,都有一定的疗补作用。山药粉具有降低血糖的作用,是糖尿病患者理想的食疗药品。山药粉能防止心血管系统脂肪沉淀,保持血管的弹性,防止动脉粥样硬化过早发生,减少皮下脂肪沉积。
麦苗粉,具有调控血糖的作用,能限制部分糖和脂肪的吸收,并使体内脂肪消耗增加,有效控制肥胖,防止动脉硬化,使血压稳定,对糖尿病、心脑血管疾病有良好改善作用。
柠檬粉,可以防治心血管疾病,能缓解钙离子促使血液凝固的作用,可预防和治疗高血压和心肌梗死,柠檬酸有收缩、增固毛细血管,降低通透性,提高凝血功能及血小板数量的作用,可缩短凝血时间和出血时间31%~71%,具有止血作用。
玉米低聚肽粉,其是以玉米蛋白粉为原料,经调浆、蛋白酶酶解、分离、过滤、喷雾干燥等工艺生产而成的。是一种新资源产品,可应用于降血压、醒酒护肝、增强免疫及增强运动能力。
黑枸杞粉,能滋补肝肾、益精明目、适用于腰膝酸软、头晕目眩、两眼昏花等症状,藏医药经典《四部医典》、《晶珠本草》等记载黑果枸杞主治心热病、心脏病、月经不调、停经等。《维吾尔药志》记载维吾尔医常用黑果枸杞果实及根皮治疗尿道结石、癣疥、齿龈出血等症,民间作滋补强壮以及降压药。现代科学研究证实了上述说法,并且认为黑果枸杞可以降低胆固醇,兴奋大脑神经,增强免疫功能,防治癌症,抗衰老和美容,黑果枸杞提取物可促进细胞免疫功能,增强淋巴细胞增殖及肿瘤坏死因子的生成,对白细胞介素Ⅱ有双向调解作用,能缓解糖尿病患者多饮多食、体重减轻症。
具体实施方式
以下实施例用于说明本发明,但不用来限制本发明的范围。
实施例1
本实施例提供一种辅助降三高组合物,所述组合物由以下重量克数的原料制备而成:地龙蛋白粉0.15克、红曲粉0.05克、纳豆粉0.045克、黑番茄提取物0.035克、山楂粉0.035克、红枣粉0.035克、薄荷提取物0.06克、魔芋粉0.05克、山药粉0.025克、麦苗粉0.025克、柠檬粉0.025克、水蜜桃提取物0.025克、玉米低聚肽粉0.07克、黑枸杞粉0.05克。
所述组合物为压片制剂。
上述组合物的制备方法如下:
称取相应重量份数的各原料,混合均匀,压制成片。
实施例2
本实施例提供一种辅助降三高组合物,所述组合物由以下重量克数的原料制备而成:地龙蛋白粉0.1克、红曲粉0.08克、纳豆粉0.03克、黑番茄提取物0.04克、山楂粉0.02克、红枣粉0.04克、薄荷提取物0.03克、魔芋粉0.08克、山药粉0.01克、麦苗粉0.04克、柠檬粉0.01克、水蜜桃提取物0.04克、玉米低聚肽粉0.05克、黑枸杞粉0.08克。
上述组合物的制备方法如下:
称取相应重量份数的各原料,混合均匀,压制成片。
实施例3
本实施例提供一种辅助降三高组合物,所述组合物由以下重量克数的原料制备而成:地龙蛋白粉0.2克、红曲粉0.03克、纳豆粉0.05克、黑番茄提取物0.02克、山楂粉0.04克、红枣粉0.02克、薄荷提取物0.09克、魔芋粉0.03克、山药粉0.03克、麦苗粉0.01克、柠檬粉0.04克、水蜜桃提取物0.01克、玉米低聚肽粉0.1克、黑枸杞粉0.03克。
上述组合物的制备方法如下:
称取相应重量份数的各原料,混合均匀,压制成片。
实施例4
本实施例提供一种辅助降三高组合物,所述组合物由以下重量克数的原料制备而成:地龙蛋白粉0.13克、红曲粉0.07克、纳豆粉0.04克、黑番茄提取物0.04克、山楂粉0.03克、红枣粉0.04克、薄荷提取物0.05克、魔芋粉0.07克、山药粉0.02克、麦苗粉0.03克、柠檬粉0.02克、水蜜桃提取物0.03克、玉米低聚肽粉0.06克、黑枸杞粉0.07克。
上述组合物的制备方法如下:
称取相应重量份数的各原料,混合均匀,压制成片。
实施例5
本实施例提供一种辅助降三高组合物,所述组合物由以下重量克数的原料制备而成:地龙蛋白粉0.17克、红曲粉0.04克、纳豆粉0.05克、黑番茄提取物0.03克、山楂粉0.04克、红枣粉0.03克、薄荷提取物0.07克、魔芋粉0.04克、山药粉0.03克、麦苗粉0.02克、柠檬粉0.03克、水蜜桃提取物0.02克、玉米低聚肽粉0.08克、黑枸杞粉0.04克。
上述组合物的制备方法如下:
称取相应重量份数的各原料,混合均匀,压制成片。
本发明选取300例三高患者,采用本发明实施例1-5提供的辅助降三高组合物对上述测试者进行测试。每天服用降三高压片3-4粒,测试期间停止服用其他降三高药物,同时避免其他外界因素的影响。
经过一段时间的测试后,观察患者情况,5组实施例总的效果如下:无效0%、有效果13%,效果明显37%,效果显著50%,即本发明提供的辅助降三高组合物的有效率为100%。可见,本发明提供的辅助降三高组合物对三高患者有特别好的效果。
上述300例测试者中的典型案例,如下:
效果例1:
周女士,症状:血脂6.47,血压高129低77,血糖4.2,心率69。2018.2.5开始服用实施例1提供的辅助降三高组合物,每天3-4粒,连续服用17天。改善:血脂4.04,血压高129低77,血糖4.2,心率67。
效果例2:
邱先生,症状:总胆固醇4.94。2018.3.7开始服用实施例2提供的辅助降三高组合物,每天3-4粒,连续服用14天。改善:总胆固醇4.22。
效果例3:
沈先生,症状:甘油三酯1.77,血糖3.83。2017.12.5开始服用实施例3提供的辅助降三高组合物,每天3-4粒,连续服用11天。改善:甘油三酯1.22,血糖3.79。
效果例4:
陈女士,症状:血糖5.2,总胆固醇4.29,血压高139低94,尿酸0.74。2017.11.15开始服用实施例4提供的辅助降三高组合物,每天3-4粒,连续服用11天。改善:血糖4.9,总胆固醇3.21,血压高128低94,尿酸0.65。
效果例5:
章先生,症状:总胆固醇4.63,空腔血糖5.9,尿酸0.47。2018.1.7开始服用实施例5提供的辅助降三高组合物,每天3-4粒,连续服用8天。改善:总胆固醇4.19,空腔血糖5.8,尿酸0.42。
效果例6:
晴天女士,症状:总胆固醇3.36,血糖6.4。2018.1.6开始服用实施例1提供的辅助降三高组合物,每天3-4粒,连续服用7天。改善:总胆固醇2.90,血糖6.2。
效果例7:
马女士,症状:总胆固醇3.98,血压高压130低压90,血糖6.9。2017.11.5开始服用实施例2提供的辅助降三高组合物,每天3-4粒,连续服用4天。改善:总胆固醇3.83,血压高压110低压80,血糖6.5。
效果例8:
王女士,症状:总胆固醇4.04,血糖4.7。2018.3.4开始服用实施例3提供的辅助降三高组合物,每天3-4粒,连续服用4天。改善:总胆固醇3.7,血糖4.5。
效果例9:
周先生,症状:总胆固醇5.52,血糖5.51,尿酸383.4。2018.3.4开始服用实施例4提供的辅助降三高组合物,每天3-4粒,连续服用7天。改善:总胆固醇3.92,血糖5.35,尿酸365。
效果例10:
彭先生,症状:总胆固醇5.47,血压高压133低压92,血糖5.32。2018.1.24开始服用实施例5提供的辅助降三高组合物,每天3-4粒,连续服用7天。改善:总胆固醇5.11,血压高压132低压91,血糖5.1。
虽然,上文中已经用一般性说明及具体实施例对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (6)
1.一种辅助降三高组合物,其特征在于,所述组合物由以下重量份数的原料制备而成:地龙蛋白粉0.1-0.2份、红曲粉0.03-0.08份、纳豆粉0.03-0.05份、黑番茄提取物0.02-0.04份、山楂粉0.02-0.04份、红枣粉0.02-0.04份、薄荷提取物0.03-0.09份、魔芋粉0.03-0.08份、山药粉0.01-0.03份、麦苗粉0.01-0.04份、柠檬粉0.01-0.04份、水蜜桃提取物0.01-0.04份、玉米低聚肽粉0.05-0.1份、黑枸杞粉0.03-0.08份。
2.根据权利要求1所述的辅助降三高组合物,其特征在于,所述组合物由以下重量份数的原料制备而成:地龙蛋白粉0.13-0.17份、红曲粉0.04-0.07份、纳豆粉0.04-0.05份、黑番茄提取物0.03-0.04份、山楂粉0.03-0.04份、红枣粉0.03-0.04份、薄荷提取物0.05-0.07份、魔芋粉0.04-0.07份、山药粉0.02-0.03份、麦苗粉0.02-0.03份、柠檬粉0.02-0.03份、水蜜桃提取物0.02-0.03份、玉米低聚肽粉0.06-0.08份、黑枸杞粉0.04-0.07份。
3.根据权利要求1所述的辅助降三高组合物,其特征在于,所述组合物由以下重量份数的原料制备而成:地龙蛋白粉0.15份、红曲粉0.05份、纳豆粉0.045份、黑番茄提取物0.035份、山楂粉0.035份、红枣粉0.035份、薄荷提取物0.06份、魔芋粉0.05份、山药粉0.025份、麦苗粉0.025份、柠檬粉0.025份、水蜜桃提取物0.025份、玉米低聚肽粉0.07份、黑枸杞粉0.05份。
4.根据权利要求1-3中任一项所述的辅助降三高组合物,其特征在于,所述组合物为压片制剂。
5.一种如权利要求1-3中任一项所述的辅助降三高组合物的制备方法,其特征在于,所述方法如下:
称取相应重量份数的各原料,混合均匀,压制成片。
6.一种如权利要求1-3中任一项所述的组合物在降高血压、降高血糖、降高血脂药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810746064.4A CN109090597A (zh) | 2018-07-09 | 2018-07-09 | 一种辅助降三高组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810746064.4A CN109090597A (zh) | 2018-07-09 | 2018-07-09 | 一种辅助降三高组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109090597A true CN109090597A (zh) | 2018-12-28 |
Family
ID=64845927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810746064.4A Pending CN109090597A (zh) | 2018-07-09 | 2018-07-09 | 一种辅助降三高组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109090597A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110250524A (zh) * | 2019-07-31 | 2019-09-20 | 无棣珍康生物科技有限公司 | 一种地龙蛋白复合片及其制备方法 |
CN112655974A (zh) * | 2021-01-29 | 2021-04-16 | 安徽天凯生物科技有限公司 | 一种调节三高产品配方 |
CN113057336A (zh) * | 2021-04-15 | 2021-07-02 | 熊夜 | 一种辅助降三高的营养组合物及其制备方法 |
CN114081172A (zh) * | 2020-08-25 | 2022-02-25 | 上海屹泽生物科技有限公司 | 一种控血糖控血压组合物、控血糖控血压压片糖果及其制备方法 |
CN115299596A (zh) * | 2021-11-10 | 2022-11-08 | 山东安然纳米实业发展有限公司 | 一种包含人参干细胞的辅助降血脂组合物及其应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104208654A (zh) * | 2014-09-05 | 2014-12-17 | 洛阳华以生物工程有限公司 | 一种以地龙蛋白提取物为主的保健配方 |
CN105360789A (zh) * | 2014-08-18 | 2016-03-02 | 天津鑫泽众生物技术有限公司 | 一种食用地龙蛋白营养冲剂及其加工工艺 |
CN105707863A (zh) * | 2016-03-10 | 2016-06-29 | 劲膳美生物科技股份有限公司 | 降血脂医学配方食品 |
CN105707876A (zh) * | 2016-04-12 | 2016-06-29 | 通泰心脑健康管理有限公司 | 一种具有稳定和溶解斑块的饮食组合物及其制备方法和用途 |
CN105831749A (zh) * | 2016-04-15 | 2016-08-10 | 劲膳美生物科技股份有限公司 | 高血压医学配方食品 |
CN106858586A (zh) * | 2017-01-14 | 2017-06-20 | 威海紫光科技园有限公司 | 一种防治心脑血管疾病的地龙蛋白纳豆人参复合蛋白产品 |
CN108065015A (zh) * | 2017-11-27 | 2018-05-25 | 余雪平 | 含地龙蛋白的降血脂压片糖果及其制备方法 |
-
2018
- 2018-07-09 CN CN201810746064.4A patent/CN109090597A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105360789A (zh) * | 2014-08-18 | 2016-03-02 | 天津鑫泽众生物技术有限公司 | 一种食用地龙蛋白营养冲剂及其加工工艺 |
CN104208654A (zh) * | 2014-09-05 | 2014-12-17 | 洛阳华以生物工程有限公司 | 一种以地龙蛋白提取物为主的保健配方 |
CN105707863A (zh) * | 2016-03-10 | 2016-06-29 | 劲膳美生物科技股份有限公司 | 降血脂医学配方食品 |
CN105707876A (zh) * | 2016-04-12 | 2016-06-29 | 通泰心脑健康管理有限公司 | 一种具有稳定和溶解斑块的饮食组合物及其制备方法和用途 |
CN105831749A (zh) * | 2016-04-15 | 2016-08-10 | 劲膳美生物科技股份有限公司 | 高血压医学配方食品 |
CN106858586A (zh) * | 2017-01-14 | 2017-06-20 | 威海紫光科技园有限公司 | 一种防治心脑血管疾病的地龙蛋白纳豆人参复合蛋白产品 |
CN108065015A (zh) * | 2017-11-27 | 2018-05-25 | 余雪平 | 含地龙蛋白的降血脂压片糖果及其制备方法 |
Non-Patent Citations (2)
Title |
---|
房泽海等: "鲜地龙平喘活性蛋白提取工艺研究 ", 《中成药》 * |
石永芳: "生物制剂地龙蛋白的研究进展 ", 《山东化工》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110250524A (zh) * | 2019-07-31 | 2019-09-20 | 无棣珍康生物科技有限公司 | 一种地龙蛋白复合片及其制备方法 |
CN114081172A (zh) * | 2020-08-25 | 2022-02-25 | 上海屹泽生物科技有限公司 | 一种控血糖控血压组合物、控血糖控血压压片糖果及其制备方法 |
CN112655974A (zh) * | 2021-01-29 | 2021-04-16 | 安徽天凯生物科技有限公司 | 一种调节三高产品配方 |
CN113057336A (zh) * | 2021-04-15 | 2021-07-02 | 熊夜 | 一种辅助降三高的营养组合物及其制备方法 |
CN115299596A (zh) * | 2021-11-10 | 2022-11-08 | 山东安然纳米实业发展有限公司 | 一种包含人参干细胞的辅助降血脂组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109090597A (zh) | 一种辅助降三高组合物及其制备方法和应用 | |
CN104054769B (zh) | 一种治疗心血管疾病的功能面包及其制作方法 | |
CN105727081A (zh) | 一种用于治疗痛风的保健品组合物 | |
KR101579845B1 (ko) | 남성호르몬 증가, 지구력 및 근력 증가, 체지방 및 혈중지질 감소, 정자수 및 정자운동성 증가를 통해 남성갱년기 증상인 무기력증과 활력저하, 근력저하, 체지방량 증가, 피로감 및 스트레스 증가를 개선하고 예방 및 치료하는 호로파 또는 호로파를 함유하는 복합조성물 | |
CN108175024A (zh) | 一种向日葵花粉固体饮料及制备方法 | |
CN103919127A (zh) | 一种保健食品及其制作方法 | |
CN105707876B (zh) | 一种具有稳定和溶解斑块的饮食组合物及其制备方法和用途 | |
CN111449246A (zh) | 一种含肌肽组合物及其在调节尿酸中的应用 | |
CN107613998A (zh) | 作为有效成分含有阿魏菇水提取物的代谢性疾病的预防和治疗用药物组合物或健康功能性食品 | |
KR101300016B1 (ko) | 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물 | |
CN104857034A (zh) | 一种防治心脑血管疾病的功能食品及其制备方法 | |
KR101859166B1 (ko) | 인삼이 함유된 한약재 추출물을 유효성분으로 함유하는 숙취 해소용 조성물 | |
CN112791175A (zh) | 提高人体新陈代谢机能和排出代谢废物的中西药组合物及其制备方法 | |
KR20180026190A (ko) | 한약재 추출물(cjs03)을 함유하는 불면증 개선, 예방 또는 치료용 조성물 | |
JPWO2005094858A1 (ja) | 抗糖尿病用組成物 | |
CN109549206A (zh) | 一种溶栓及预防心血管疾病的功能性食品及其制备方法 | |
KR101227922B1 (ko) | 파파야 퓌레 조제품 및 그 제조방법 | |
KR101391647B1 (ko) | 항비만 조성물 | |
CN106729518A (zh) | 一种降血压的茶饮料及其制备方法与应用 | |
KR20210029462A (ko) | 혈류 개선용 건강기능식품 조성물 및 이의 제조 방법 | |
CN112089784A (zh) | 中药组合物在制备预防、治疗动脉粥样硬化所致疾病的药物中的应用 | |
KR101093006B1 (ko) | 미생물을 이용한 우황 청심원 원료 함유 건강식품의 제조방법 및 그 제조방법에 의해 제조된 건강식품 | |
KR20160056426A (ko) | 명월초 열수 추출물을 유효성분으로 함유하는 운동능력 증강 및 피로 회복용 조성물 | |
CN108991358A (zh) | 一种辅助降血脂、降血糖、缓解痛风保健食品及生产方法 | |
KR102310233B1 (ko) | 혈류 개선용 건강기능식품 조성물 및 이의 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181228 |